Targeted axillary dissection, often abbreviated as TAD, has emerged as a precise alternative to full axillary lymph node dissection in breast cancer patients who present with positive nodes before neoadjuvant chemotherapy. By marking the biopsy proven positive node before treatment and identifying it accurately at surgery, TAD allows the surgical team to confirm nodal response while limiting morbidity. This article explains how TAD after neoadjuvant chemotherapy works, why accurate node identification matters, and how modern surgical marker navigation supports reliable target node retrieval.
Targeted axillary dissection is a surgical approach used in breast cancer patients with biopsy proven axillary lymph node involvement before systemic treatment. It combines sentinel lymph node biopsy with selective removal of the previously identified positive node, which is marked before neoadjuvant therapy. The aim is to assess whether the chemotherapy has eradicated nodal disease, while avoiding the morbidity of a complete axillary lymph node dissection in patients who achieve nodal downstaging.
For a general overview of the procedure, see Targeted Axillary Dissection. For background on related sentinel node surgery, see Sentinel Lymph Node Dissection.
Neoadjuvant chemotherapy is increasingly used in patients with locally advanced or node positive breast cancer. A significant proportion of these patients achieve a pathologic complete response in the axilla, meaning the chemotherapy has cleared the lymph node disease. Historically, all patients with initial nodal involvement underwent complete axillary lymph node dissection regardless of response, exposing many to long term complications including lymphedema, shoulder dysfunction and chronic pain.
TAD allows surgeons to selectively evaluate the previously involved node together with sentinel nodes, which can identify patients in whom further axillary surgery may be safely avoided. For broader context on the postchemotherapy surgical scenario, see Tumor Bed Localization After Neoadjuvant Therapy.
The core challenge in TAD after neoadjuvant chemotherapy is reliably identifying the specific node that was biopsy proven positive before treatment. After several months of systemic therapy, the node may shrink, change in appearance or migrate, and the sentinel node identified during surgery is not always the same as the previously involved node.
Published evidence indicates that wire guided TAD can fail in 10 to 33 percent of cases due to wire dislocation or inability to locate the marked node. Accurate marking and retrieval are therefore essential to make TAD a dependable alternative to complete axillary dissection.
For more on the principles of accurate lesion identification, see Breast Cancer Localization.
To support reliable TAD, a marker is placed in the biopsy proven positive node at the time of diagnosis, before neoadjuvant chemotherapy begins. The marker must remain stable throughout multiple cycles of treatment, often spanning several months, and must be reliably detectable at surgery. Clip markers placed at biopsy can serve this purpose, but their detection at surgery still requires a localization technique such as wire guidance, radioactive seed placement or a surgical marker that can be located in real time.
Guidance from organizations indexed by the National Comprehensive Cancer Network emphasizes the importance of axillary staging strategies tailored to nodal status and response to systemic therapy.
An important clinical observation is that in a substantial subset of patients, the biopsy proven positive node is not the same as the sentinel node identified at surgery. Reported figures suggest the target node differs from the sentinel node in approximately 30 percent of TAD cases, rising further in patients with residual nodal disease. This makes independent marking of the confirmed positive node essential, since relying on sentinel node biopsy alone could miss residual disease in these patients.
A study by Egle and colleagues at the Medical University of Innsbruck, published in Breast Care in January 2025 (doi: 10.1159/000541704), evaluated magnetic surgical marker navigation using the Pintuition® system for TAD after neoadjuvant chemotherapy. The retrospective case series included 20 patients with histologically verified node positive breast cancer who underwent TAD between April 2022 and March 2023.
The study reported a 100 percent target node identification rate at surgery in all 20 patients, with all markers retrieved and no complications linked to marker placement or the surgical procedure. In 30 percent of cases the target node differed from the sentinel node, rising to 44 percent in patients with residual disease, confirming the value of independent marking of the confirmed positive node. The marker remained in place across the full course of chemotherapy in every patient, demonstrating stability over the treatment interval. A study summary is available in the clinical one pager.
Additional research indexed on PubMed provides further context on the evolving axillary management strategies in node positive breast cancer treated with neoadjuvant therapy.
Marker placement at the time of biopsy, rather than as a separate procedure shortly before surgery, can simplify the patient pathway by combining diagnosis and localization in a single visit. A marker that can remain in place throughout the chemotherapy interval and does not require same day coordination with radiology gives both departments more flexibility in scheduling, which can reduce delays and improve the patient experience.
Sirius Medical developed the Pintuition System® to support precise lesion and node localization in breast cancer surgery. The Pintuition Marker® is a non radioactive magnetic marker that can be placed under standard image guidance and is approved for long term implantation, making it suitable for marking lymph nodes before neoadjuvant chemotherapy and identifying them months later at surgery.
During TAD, the Pintuition System® provides real time distance and directional feedback to the marker, supporting reliable target node identification in patients undergoing axillary surgery after neoadjuvant treatment.
Learn how Pintuition® can support precision, workflow efficiency and confidence in targeted axillary dissection and other complex breast cancer procedures. Request a demo or explore the clinical overview for more information.
Disclaimer
This article is intended for informational purposes only and should not be considered medical advice. Clinical decisions should always be made by qualified healthcare professionals based on individual patient needs and current guidelines.